Teva presents new data supporting safety, tolerability and target engagement of anti-tl1a (tev-‘574) antibody at the 2024 ecco annual meeting

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced positive safety, tolerability, and pharmacokinetic data for its anti-tl1a (tev-'574) asset, a potentially best-in-class human igg1 monoclonal antibody that targets the tumor necrosis factor (tnf)-like ligand 1a (tl1a) and is designed to offer both anti-inflammatory and anti-fibrotic effects.1-3 the data show the rapid and sust.
TEVA Ratings Summary
TEVA Quant Ranking